Abstract
Objectives
Niemann–Pick type C (NPC) disease is a rare progressive neurodegenerative condition that is characterized by the accumulation of cholesterol, glycosphingolipids, and sphingosine in lysosomes. Patients have various systemic and neurological findings depending on their age at onset. This disease is caused by the autosomal recessive transmission of mutations in the NPC1 and NPC2 genes; patients have mutations mainly in the NPC1 gene (95%) and the majority of them are point mutations located in the exonic regions.
Case presentation
Here, we presented three cousins with hepatosplenomegaly and progressive neurodegeneration who were diagnosed with visceral-neurodegenerative NPC disease. Their parents were relatives, and they had a history of sibling death with similar complaints. Bone marrow smear showed foamy cells in patient 1. Vertical supranuclear gaze palsy was not present in all cases. Sphingomyelinase (SM) activities were almost normal to exclude NPA or NPB. Filipin staining was performed in patient 2 and showed a massive accumulation of unesterified cholesterol The NPC1 gene analysis of the three patients showed a novel homozygous c.1553+5G>A intronic mutation. cDNA analysis was performed from the patient 3 and both parents. It was observed that exon 9 was completely skipped in the homozygous mutant baby. Both the normal and the exon 9-skipped transcripts have been detected in the parents.
Conclusions
When combined with the filipin staining and the patients’ clinical outcomes, this mutation is likely to be deleterious. Moreover, cDNA sequencing supports the pathogenicity of this novel variant.
Acknowledgments
We would like to thank Professor Sultan D. Aydoğdu and we remember her with respect. The filipin test was studied at Laboratoire de Biologie Medicale Multi Sites du Chu de Lyon. Also, thanks to Marie T Vanier for her support on this issue.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The local Institutional Review Board deemed the study exempt from review.
References
1. McKay Bounford, K, Gissen, P. Genetic and laboratory diagnostic approach in Niemann Pick disease type C. J Neurol 2014;261:569–75. https://doi.org/10.1007/s00415-014-7386-8.Search in Google Scholar PubMed PubMed Central
2. Geberhiwot, T, Moro, A, Dardis, A, Ramaswami, U, Sirrs, S, Marfa, MP, et al.. Consensus clinical management guidelines for Niemann-Pick disease type C. Orphanet J Rare Dis 2018;13:50–69. https://doi.org/10.1186/s13023-018-0785-7.Search in Google Scholar PubMed PubMed Central
3. Seker Yilmaz, B, Baruteau, J, Rahim, AA, Gissen, P. Clinical and molecular features of early infantile Niemann Pick Type C disease. Int J Mol Sci 2020;21:5059–90. https://doi.org/10.3390/ijms21145059.Search in Google Scholar PubMed PubMed Central
4. Imrie, J, Heptinstall, L, Knight, S, Strong, K. Observational cohort study of the natural history of Niemann-Pick disease type C in the UK: a 5-year update from the UK clinical database. BMC Neurol 2015;15:257–80. https://doi.org/10.1186/s12883-015-0511-1.Search in Google Scholar PubMed PubMed Central
5. Park, WD, O’Brien, JF, Lundquist, PA, Kraft, DL, Vockley, CW, Karnes, PS, et al.. Identification of 58 novel mutations in Niemann-Pick disease type C: correlation with biochemical phenotype and importance of PTC1-like domains in NPC1. Hum Mutat 2003;22:313–25. https://doi.org/10.1002/humu.10255.Search in Google Scholar PubMed
6. Di Leo, E, Panico, F, Tarugi, P, Battisti, C, Federico, A, Calandra, S. A point mutation in the lariat branch point of intron 6 of NPC1 as the cause of abnormal pre-mRNA splicing in Niemann-Pick type C disease. Hum Mutat 2004;24:440–8. https://doi.org/10.1002/humu.9287.Search in Google Scholar PubMed
7. Millat, G, Marçais, C¸ Tomasetto, C, Chikh, K, Fensom, AH, Harzer, K, et al.. Niemann-Pick C1 disease: correlations between NPC1 mutations, levels of NPC1 protein, and phenotypes emphasize the functional significance of the putative sterol-sensing domain and of the cysteine-rich luminal loop. Am J Hum Genet 2001;68:1373–85. https://doi.org/10.1086/320606.Search in Google Scholar PubMed PubMed Central
8. Sun, X, Marks, DL, Park, WD, Wheatley, CL, Puri, V, O’Brien, JF, et al.. Niemann-Pick C variant detection by altered sphingolipid trafficking and correlation with mutations within a specific domain of NPC1. Am J Hum Genet 2001;68:1361–72. https://doi.org/10.1086/320599.Search in Google Scholar PubMed PubMed Central
9. Fernandez-Valero, EM, Ballart, A, Iturriaga, C, Lluch, M, Macias, J, Vanier, MT, et al.. Identification of 25 new mutations in 40 unrelated Spanish Niemann-Pick type C patients: genotype-phenotype correlations. Clin Genet 2005;68:245–54. https://doi.org/10.1111/j.1399-0004.2005.00490.x.Search in Google Scholar PubMed
10. Blundell, J, Frisson, S, Chakrapani, A, Gissen, P, Hendriksz, C, Vijay, S, et al.. Oculomotor abnormalities in children with Niemann-Pick type C. Mol Genet Metabol 2018;123:159–68. https://doi.org/10.1016/j.ymgme.2017.11.004.Search in Google Scholar PubMed
11. Sidhu, R, Mondjinou, Y, Qian, M, Haowei, S, Kubar, BA, Hong, X, et al.. N-acyl-O-phosphocolineserines: structures of a novel class of lipids that are biomarkers for Niemann-Pick C1 disease. J Lipid Res 2019;60:1410–24. https://doi.org/10.1194/jlr.ra119000157.Search in Google Scholar
12. Mazzacuva, F, Mills, P, Mills, K, Camuzeaux, S, Gissen, P, Nicoli, ER, et al.. Identification of novel bile acids as biomarkers for the early diagnosis of Niemann-Pick C disease. FEBS Lett 2016;590:1651–62. https://doi.org/10.1002/1873-3468.12196.Search in Google Scholar
13. Ory, DS, Ottinger, EA, Farhat, NY, King, KA, Jiang, X, Weissfeld, L, et al.. Intrathecal 2-hydroxypropyl-betacyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial. Lancet 2017;390:1758–68. https://doi.org/10.1016/s0140-6736(17)31465-4.Search in Google Scholar
14. Héron, B, Valayannopoulos, V, Baruteau, J, Chabrol, B, Ogier, H, Latour, P, et al.. Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C. Orphanet J Rare Dis 2012;7:36–50. https://doi.org/10.1186/1750-1172-7-36.Search in Google Scholar PubMed PubMed Central
© 2021 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Review Article
- Nephrogenic diabetes insipidus: a comprehensive overview
- Original Articles
- Prevalence of type 2 diabetes mellitus, metabolic syndrome, and related morbidities in overweight and obese children
- Impact of sports participation on components of metabolic syndrome in adolescents: ABCD growth study
- Expected or unexpected clinical findings in liver glycogen storage disease type IX: distinct clinical and molecular variability
- Evaluation of patients with phenylalanine metabolism disorder: a single center experience
- The association of grandparental co-residence and dietary knowledge with excess body weight among children aged 7–15 years in China
- Clinical characteristics of polyglandular autoimmune syndromes in pediatric age: an observational study
- Serum kisspeptin, leptin, neuropeptide Y, and neurokinin B levels in adolescents with polycystic ovary syndrome
- Ultrasonographic measurements of the testicular volume in Turkish boys aged 0–8 years and comparison with international references
- Fructose 1,6 bisphosphatase deficiency: outcomes of patients in a single center in Turkey and identification of novel splice site and indel mutations in FBP1
- Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial
- Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency
- Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy
- Letter to the Editor
- Correspondence on “Obesity after the Covid-19 pandemic”
- Case Reports
- An unusual presentation of primary adrenal insufficiency with new onset type 1 diabetes: case report and review of the literature
- Niemann–Pick type C disease with a novel intronic mutation: three Turkish cases from the same family
- Weight management in youth with rapid-onset obesity with hypothalamic dysregulation, hypoventilation, autonomic dysregulation, and neural crest tumor (ROHHAD-NET): literature search and case report
- Successful use of cinacalcet monotherapy in the management of siblings with homozygous calcium-sensing receptor mutation
Articles in the same Issue
- Frontmatter
- Review Article
- Nephrogenic diabetes insipidus: a comprehensive overview
- Original Articles
- Prevalence of type 2 diabetes mellitus, metabolic syndrome, and related morbidities in overweight and obese children
- Impact of sports participation on components of metabolic syndrome in adolescents: ABCD growth study
- Expected or unexpected clinical findings in liver glycogen storage disease type IX: distinct clinical and molecular variability
- Evaluation of patients with phenylalanine metabolism disorder: a single center experience
- The association of grandparental co-residence and dietary knowledge with excess body weight among children aged 7–15 years in China
- Clinical characteristics of polyglandular autoimmune syndromes in pediatric age: an observational study
- Serum kisspeptin, leptin, neuropeptide Y, and neurokinin B levels in adolescents with polycystic ovary syndrome
- Ultrasonographic measurements of the testicular volume in Turkish boys aged 0–8 years and comparison with international references
- Fructose 1,6 bisphosphatase deficiency: outcomes of patients in a single center in Turkey and identification of novel splice site and indel mutations in FBP1
- Benefits of metformin add-on insulin therapy (MAIT) for HbA1c and lipid profile in adolescents with type 1 diabetes mellitus: preliminary report from a double-blinded, placebo-controlled, randomized clinical trial
- Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency
- Evaluation of endocrinological involvement and metabolic status in patients with Gaucher disease Type 1 and Fabry disease under enzyme replacement therapy
- Letter to the Editor
- Correspondence on “Obesity after the Covid-19 pandemic”
- Case Reports
- An unusual presentation of primary adrenal insufficiency with new onset type 1 diabetes: case report and review of the literature
- Niemann–Pick type C disease with a novel intronic mutation: three Turkish cases from the same family
- Weight management in youth with rapid-onset obesity with hypothalamic dysregulation, hypoventilation, autonomic dysregulation, and neural crest tumor (ROHHAD-NET): literature search and case report
- Successful use of cinacalcet monotherapy in the management of siblings with homozygous calcium-sensing receptor mutation